Research
Intellectual rigor. Sound science. Innovative approaches. These are hallmarks of Crinetics and how we maintain a healthy pipeline.
We focus on the discovery of drugs for rare endocrine diseases and related tumors with:
- High unmet medical need
- Established biology
- Biomarker endpoints
- Early Phase POC
- Efficient registration trials
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
Acromegaly (PATHFNDR-1, 2)
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
Acromegaly (PATHFNDR-1, 2)
Paltusotine(oral SST2 agonist)
In development for the treatment of acromegaly, neuroendocrine tumors (NETs) and carcinoid syndrome, our lead product candidate establishes a new class of oral, selective, nonpeptide, somatostatin receptor type 2 (SST2) agonist.
CRN04777(oral SST5 agonist)
This is the first oral, selective, somatostatin type 5 (SST5) receptor agonist designed to treat congenital hyperinsulinism (congenital HI).
CRN04894(oral ACTH antagonist)
This is the first oral, selective ACTH antagonist in development for the treatment of Cushing’s disease and other diseases of excess ACTH, such as congenital adrenal hyperplasia (CAH).